Boston, MA -- (SBWIRE) -- 06/06/2014 -- Despite Netherlands' expectations for a return to positive economic growth in 2014, its government will continue with austerity measures to comply with EU budget criteria. Drugmakers have generally charged what the market will bear in both developed and emerging markets. With the advent of health economics, coupled with increasing budget deficits, there will be more caps on medicine expenditure in the near future, particularly on essential drugs. We therefore maintain that further restrictions on medicines prices will work to create a subdued outlook for patented and generic drugmakers operating in the country.
View Full Report Details and Table of Contents
Headline Expenditure Projections
- Pharmaceuticals: EUR6.09bn (USD8.04bn) in 2013 to EUR5.94bn (USD7.78bn) in 2014; -2.4% in local currency terms and -3.1% in US dollar terms.
- Healthcare: EUR74.69bn (USD98.59bn) in 2013 to EUR76.21bn (USD99.83bn) in 2014; 2.0% in local currency terms and -1.3% in US dollar terms.
The Netherlands continues to rank in the lower half of BMI's Pharmaceutical Risk/Reward Ratings (RRRs) for the 15 key Western European markets, falling one place to 11th in our ratings for Q314. The country fell from eighth in Q413. At an unchanged 66, its overall RRR score remains only slightly below the regional average of 67. This was the result of the rise of Finland and the incorporation of Denmark in our ratings system, both of which overtook the Netherlands. While the country offers drugmakers a relatively low-risk operating environment, poor market prospects - due to pressures on pricing and reimbursement and the market's maturity - will continue to weigh down the country's overall standing.
Key Trends And Developments
In April, The Dutch Health Performance Report had found that Dutch families spend up to a quarter of their incomes on healthcare. Families with an aggregate income of less than EUR50,000 (USD69,324) spent about EUR11,500 (USD15,944) on health costs in 2012 or around 23.5% of their incomes, the report stated. Of the EUR11,500 (USD15,944), around EUR6,000 (USD8,319) was spent on health insurance premiums, while the remaining EUR5,000 (USD6,932) was related to exceptional medical expenses, the report added. The figure relates to gross income and includes premiums and taxes, but not out-of-pocket payments.
The net loss of Netherlands-based biotechnology company Pharming Group narrowed to EUR14.8mn (USD20.37mn) in FY13 ended December 31 2013, compared with EUR24.1mn (USD33.18mn) in 2012. The company's turnover declined to EUR7mn (USD9.63mn) during the period, compared with EUR10.9mn (USD15mn) the previous year. The company's cash reserves increased to more than EUR19mn (USD26.15mn) as of late December 2013, compared with EUR6.3mn (USD8.67mn) in the same period the previous year.
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Healthcare research reports at Fast Market Research
You may also be interested in these related reports:
- Thailand Pharmaceuticals & Healthcare Report Q3 2014
- Nigeria Pharmaceuticals & Healthcare Report Q3 2014
- Australia Pharmaceuticals & Healthcare Report Q3 2014
- Central America Pharmaceuticals & Healthcare Report Q3 2014
- Mexico Pharmaceuticals & Healthcare Report Q3 2014
- Croatia Pharmaceuticals & Healthcare Report Q3 2014
- Latvia Pharmaceuticals & Healthcare Report Q3 2014
- Algeria Pharmaceuticals & Healthcare Report Q3 2014
- Kenya Pharmaceuticals & Healthcare Report Q3 2014
- Pakistan Pharmaceuticals & Healthcare Report Q3 2014